ROLE OF NEW ANTIANGIOGENIC DRUGS IN THE SECOND-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Angiogenesis plays a major role in the growth and progression of non-small cell lung cancer (NSCLC), and there is increasing interest in the development of therapies that block this particular aspect of tumorigenesis. Bevacizumab was the first approved inhibitor of angiogenesis after demonstrating improved progression-free survival and overall survival in combination with chemotherapy in treating NSCLC. However, the benefit of bevacizumab is only modest and transient as the tumors inevitably develop resistance to this particular treatment. Therefore, new therapies are being developed that attempt to inhibit angiogenesis through several different pathways. One promising new drug, nintedanib, is an oral triple angiokinase inhibitor that acts by blocking not only VEGFR, but also FGFR and PDGFR, which are involved in the development of resistance to bevacizumab. This article discusses the rationale for this approach and summarizes the clinical trial data on nintedanib, including the two most recent phase III trials.

Full Text

Restricted Access

About the authors

A. I Semenova

Email: mirannia@yandex.ru
FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH MD, Senior Researcher at the Department of Innovative Methods in Therapeutic Oncology and Rehabilitation, Medical Oncologist at the Department of Chemotherapy and Innovative Technologies Saint-Petersburg

S. A Protsenko

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH Saint-Petersburg

A. V Novik

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH Saint-Petersburg

D. H Latipova

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH Saint-Petersburg

G. M Teletayeva

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH Saint-Petersburg

T. Y Semiglazova

FSBI «SRI of Oncology n.a. N.N. Petrov» of RMH Saint-Petersburg

References

  1. Ferlay J., Soerjomataram I., Ervik M. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11. Lyon: International Agency for Research on Cancer, 2013
  2. World Health Organization: International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_ cancer.aspx#. Accessed February 19, 2015.
  3. Langer C.J., Besse B., Gualberto A., Brambilla E., Soria J.C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010;28(36):5311-20.
  4. Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of nonsmall-cell lung cancer: implications for current and future therapies. J. Clin. Oncol. 2013;31(8):1039-49.
  5. Ettinger D.S., Akerley W., Borghaei H. Non-small cell lung cancer. J. Natl. Compr. Canc. Netw. 2012;10(10):1236-71.
  6. Leighl N.B. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr. Oncol. 2012;19:S52-58.
  7. Reck M., Popat S., Reinmuth N. Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25:iii27-39.
  8. Scagliotti G.V., Parikh P., Von Pawel J. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. J. Clin. Oncol. 2008;26(21):3543-51.
  9. Gridelli C., Ardizzoni A., Ciardiello F., Hanna N., Heymach J.V., Perrone F., Rosell R., Shepherd F.A., Thatcher N., Vansteenkiste J., De Petris L., Di Maio M., De Marinis F. Second-line treatment of advanced non-small cell lung cancer. J. Thorac. Oncol. 2008;3:430-40.
  10. Ciuleanu T., Stelmakh L., Cicenas S. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300-8.
  11. Garassino M.C., Martelli O., Broggini M., Farina G., Veronese S., Rulli E., Bianchi F., Bettini A., Longo F., Moscetti L., Tomirotti M., Marabese M., Ganzinelli M., Lauricella C., Labianca R., Floriani I., Giaccone G., Torri V., Scanni A., Marsoni S. TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981-88.
  12. Garon E.B., Ciuleanu T.E., Arrieta O., Prabhash K., Syrigos K.N., Goksel T., Park K., Gorbunova V., Kowalyszyn R.D., Pikiel J., Czyzewicz G., Orlov S.V., Lewanski C.R., Thomas M., Bidoli P., Dakhil S., Gans S., Kim J.H., Grigorescu A., Karaseva N., Reck M., Cappuzzo F., Alexandris E., Sashegyi A., Yurasov S., Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-73.
  13. Ganguli A., Wiegand P., Gao X., Carter J.A., Botteman M.F., Ray S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Qual. Life Res. 2013;22(5):1015-26.
  14. Paz-Ares L.G., Biesma B., Heigener D., vonPawel J., Eisen T., Bennouna J., Zhang L., Liao M., Sun Y., Gans S., Syrigos K., Le Marie E., Gottfried M., Vansteenkiste J., Alberola V., Strauss U.P., Montegriffo E., Ong T.J., Santoro A.; NSCLC [non-small-celllung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2012;30:3084-92.
  15. Herbst R.S., Sun Y., Eberhardt W.E. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced nonsmall-cell lung cancer (ZODIAC): a doubleblind, randomised, phase 3 trial. Lancet Oncol. 2010;11:619-26.
  16. Natale R.B., Thongprasert S., Greco F.A. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2011;29:1059-66.
  17. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., DeMarinis F., vonPawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar., Manegold C., Paul S., Paoletti P., Einhorn L., Bunn P.A. Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004;22:1589-97.
  18. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., Levitan N., Gressot L., Vincent M., Burkes R., Coughlin S., Kim Y., Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000;18:2095-103.
  19. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005;23(5):1011-27.
  20. Herbst R.S. Therapeutic options to target angiogenesis in human malignancies. Expert. Opin. Emerg. Drugs. 2006;11(4):635-50.
  21. Ellis P.M., Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit. Rev. Oncol. Hematol. 2012;84(1):47-58.
  22. Leighl N.B. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr. Oncol. 2012;19:S52-8.
  23. Gadgeel S.M. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin. Lung Cancer. 2012;13:96-106.
  24. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11:1172-83.
  25. Mok T., Gorbunova V., Juhasz E., Szima B., Burdaeva O., Orlov S., Yu C.J., Archer V., Hilton M., Delmar P., Pallaud C., Reck M. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J. Thorac. Oncol. 2014;9:848-55.
  26. Gori B., Ricciardi S., Fulvi A., Intagliata S., Del Signore E., de Marinis F. New antiangiogenics in non-small cell lung cancer treatment: VargatefГМ (BIBF 1120) and beyond. Ther. Clin. Risk Manag. 2011;7:429-40
  27. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W.J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774-82.
  28. Hilberg F., Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy. Eur. J. Cancer. 2007;2:S380.
  29. Stopfer P., Rathgen K., Bischoff D., Lüdtke S., Marzin K., Kaiser R., Wagner K., Ebner T. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297-311.
  30. Okamoto I., Kaneda H., Satoh T., Okamoto W., Miyazaki M., Morinaga R., Ueda S., Terashima M., Tsuya A., Sarashina A., Konishi K., Arao T., Nishio K., Kaiser R., Nakagawa K. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol. Cancer Ther. 2010;9:2825-33.
  31. Doebele R.C., Conkling P., Traynor A.M., Otterson G.A., Zhao Y., Wind S., Stopfer P., Kaiser R., Camidge D.R. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2012;23:2094-102.
  32. Reck M., Kaiser R., Eschbach C., Stefanic M., Love J., Gatzemeier U., Stopfer P., von Pawel J. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann. Oncol. 2011;22:1374-81.
  33. Reck M., Mellemgaard A. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. Biologics. 2015;9:47-56.
  34. Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., von Pawel J., Gottfried M., Bondarenko I., Liao M., Gann C.N., Barrueco J., Gaschler-Markefski B., Novello S.; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55.
  35. Novello S., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., von Pawel J., Gottfried M., Bondarenko I., Liao M., Barrueco J., Gaschler-Markefski B., Griebsch I., Palmer M., Reck M; LUME-Lung 1 Study Group. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomized, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur. J. Cancer. 2015;51:317-26.
  36. Hocke J., Glomb P., Kaiser R., Barrueco J., Gaschler-Markefski B. Retrospective evaluation of the futility analysis in LUME-Lung 2, a phase III trial of nintedanib (BIBF 1120) plus pemetrexed for second line NSCLC patients. Presented at the International Society for Clinical Biostatistics 35th Annual Meeting, Vienna, Austria, August 24-28, 2014.
  37. Popat S., Mellemgaard A., Fahrbach K., Martin A., Rizzo M., Kaiser P., Griebsch I., Reck M. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2015;11:409-20.
  38. Hilberg F., Haslinger C., Garin-Chesa P., Adolf G.R. Molecular correlates of clinical benefit from antiangiogenic therapy for patients with lung adenocarcinoma: a hypothesis. J. Clin. Oncol. 2014;32 Suppl:Abstr. e22080.
  39. Roth G.J., Binder R., Colbatzky F., Dallinger C., Schlenker-Herceg R., Hilberg F., Wollin S.L., Kaiser R. Nintedanib: from discovery to the clinic. J. Med. Chem. 2015;58:1053-63.
  40. Recka M., Mellemgaard A., von Pawel J., Gottfried M., Bondarenko I., Cheng Y., Zarogoulidis K., Luft A., Bennouna J., Barrueco J., Aboshady H., Hocke J., Kaiser R., Douillard J.-Y., for the LUME-Lung 1 Study. Antiangiogenic-specific adverse events in patients with non-smallcell lung cancer treated with nintedanib and docetaxel. Lung Cancer. 2015; 90:267-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies